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Background. Fanconi anaemia (FA) is an autosomal recessive, genetically heterogeneous disorder, characterised by interstrand crosslink-
induced chromosome breaks, congenital abnormalities and predisposition to malignancies. It has a prevalence of about 1/40 000 in black 
South Africans (SAs). A founder mutation in the FANCG gene occurs in the homozygous state in 77.5% of southern African blacks.
Objective. To locate additional pathogenic mutations in the FANCG gene of black FA patients who were heterozygous for the founder mutation. 
Methods. Further mutation analysis of the FANCG gene was undertaken in 7 patients clinically suspected of having FA. The parents of two 
of the patients were tested for the presence of the founder mutation to determine true heterozygosity in the patients. To clarify whether or 
not previously unreported variants were pathogenic, 58 random black SA individuals were screened.
Results. Three novel single base pair deletions, resulting in frameshift mutations (c.247delA, c.179delT and c.899delT) were identified in 3/7 
patients. A fourth patient was found to have a single base substitution resulting in a splice site mutation (c.1636+1G>A). The remaining three 
patients were not found to harbour any pathogenic mutations. Two non-pathogenic variants were also identified among the seven patients.
Conclusion. The results of this small sample suggest that a second common mutation in the FANCG gene is unlikely in this population. However, 
FANCG sequencing should be performed on patients heterozygous for the common founder mutation to attempt to confirm their diagnosis. 
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MEDICAL GENETICS
971  December 2013, Vol. 103, No. 12 (Suppl 1)   SAMJ
Fanconi anaemia (FA) is characterised by interstrand 
crosslink-induced chromosome breaks,[1] congenital 
abnormalities (including radial-ray aplasia, heart 
and kidney malformations),[2] bone marrow failure,[3] 
and predisposition to haematological and solid 
malignancies. [4] The condition is rare, with a worldwide incidence of 
about 1/300 000[5] and a minimum carrier frequency of 1/300.[6]
FA is a highly heterogeneous condition, both clinically and 
genetically, arising from mutations in 1 of at least 15 genes.[7-9] All 
forms of FA are inherited as autosomal recessive conditions except for 
FANCB, which is an X-linked disorder. Loss-of-function mutations in 
the genes that underlie each of the FA complementation groups have 
been found directly or indirectly to play a role in disrupting the DNA 
repair pathway of cells.[7]
Since the 1970s, FA has been subject to investigation in the Division of 
Human Genetics, National Health Laboratory Service and the University 
of the Witwatersrand, South Africa (SA). Initially, research focussed 
on the understanding of both the clinical manifestations and the 
underlying genetic aetiology of FA in the SA white Afrikaans population. 
Rosendorff et al.[10] estimated a minimum birth incidence of FA in white, 
Afrikaans-speaking individuals to be 1/22 000 with a carrier frequency 
of 1/77. It was postulated at the time that this increased incidence could 
be attributed to a founder effect. This hypothesis was later proved to be 
correct when Tipping et al.[11] identified multiple founder mutations in 
the FANCA gene in this population. 
Similar investigations have been undertaken in the black SA 
population. Initial reports seemed to suggest FA in black individuals 
was very rare.[12] However, Macdougall et al.[13] estimated the incidence 
of FA in this population as 1/476 000 in a case-based ascertainment 
study. More recently, gene frequency studies have shown that FA has 
a carrier frequency of 1/100 in black SA patients and therefore an 
expected birth incidence of 1/40  000.[14]. The discrepancy between 
these two incidence rates is most likely due to an under-diagnosis of 
FA at local and regional healthcare facilities. FA in this population has 
been found to be caused largely by mutations in the FANCG gene.[14] 
Evidence further suggested that the clinical manifestations of FA 
in this population were similar to those in other ethnic groups. [12] 
This finding was further confirmed in a comparative study of FA 
in various SA ethnic groups.[13] Newer studies in black patients with 
known FANCG mutations have identified both similarities and 
differences with regards to the phenotypic manifestations of FA. One 
study showed that black individuals with FANCG mutations had 
more features in common with a group of other FANCG patients than 
with a group of FANCA patients.[15] An additional study indicated 
that there were no particular features of the FANCG phenotype in 
black patients that would allow prediction regarding the prognosis of 
affected individuals.[16]
The FANCG gene maps to chromosome 9p13, is 6kb in length 
comprising 14 exons and encoding a 2.5kb mRNA transcript.[17] This 
is translated into a 622 amino acid polypeptide with a molecular 
weight of 68kDa.[18] Mutations in the FANCG gene account for 8.8% 
of FA cases worldwide.[19]
A common 7 base pair deletion founder mutation (c.637-
643delTACCGCC) in the FANCG gene has been found in the 
homozygous state in 77.5% (31/40) of South African black patients 
and in a further 5% (2/40) of patients in the heterozygous state. It 
has also been found in black patients from Swaziland, Mozambique 
and Malawi.[14] 
A number of black SA individuals, strongly suspected of having 
FA based on their clinical features, have now been found to be 
heterozygous for the c.637-643delTACCGCC founder mutation. 
There are limited diagnostic services available locally, and a reliable 
cytogenetic confirmation of FA is not always possible. This situation 
has resulted in an increased reliance on clinical and molecular 
diagnosis in these patients as opposed to chromosome fragility 
testing. 
Objective
To undertake molecular testing to identify the second FA-causing 
mutation in patients who were heterozygous for the founder mutation 
in the FANCG gene, as well as to determine whether or not other 
FANCG founder mutations exist in this population.
Methods
Seven black SA patients, strongly suspected clinically to have FA 
and heterozygous for the c.637-643delTACCGCC mutation, were 
investigated. Of the seven patients, four also underwent cytogenetic 
analysis. The parents of two of the patients were available and 
tested for the presence of the founder mutation to determine true 
heterozygosity and exclude gene conversion in the probands.
DNA sequence analysis for all 14 exons of the FANCG gene, 
using the ABI3130xl genetic analyser (Applied Biosystems), was 
undertaken. Peripheral blood was used as the source of DNA for 
the molecular analysis of these patients. The primers used in this 
study were modifications (Table 2, provided online) of those outlined 
previously.[20] Sequencing results were compared with normal 
reference sequences (accessed September 2009, Ensembl) using the 
SeqMan application of DNAstar (Lasergene). 
For variants where the pathogenicity was unclear, 58 random black SA 
individuals were screened using restriction enzyme analysis to determine 
if these changes were polymorphic. These control samples were obtained 
from the sample bank of the Division of Human Genetics. If a variant 
is identified in the normal population at polymorphic frequencies, it is 
unlikely to be the cause of disease in a patient.
Ethics clearance was obtained for this study from the Human 
Research Ethics Committee (HREC), University of the Witwatersrand. 
Results 
Screening of the entire coding region as well as the flanking intronic 
regions of the FANCG gene was undertaken in the seven patients. A 
second disease-causing mutation was found in 4/7 patients (FA82, 
FA121, FA199 and FA465) (Table 1). 
Although a second pathogenic mutation was not identified in the 
FANCG gene of the remaining three patients (FA189, FA312 and 
FA402), the presence of large deletions, insertions or rearrangements 
cannot be excluded as the causal mutations in these patients. 
Unfortunately, dosage analysis by multiplex ligation-dependent probe 
amplification (MLPA) is not commercially available for the FANCG 
gene. Cost has prevented the development of an in-house assay. 
The parents of patients FA189 and FA312 were tested for the 
common founder mutation (c.637-643delTACCGCC) and in both 
cases only one parent was found to be heterozygous for this mutation. 
Patient FA402 was lost to follow-up and therefore molecular analysis 
of the patient’s parents was not performed. Sequencing of the parents’ 
FANCG genes for non-founder mutations has not been performed. 
Frameshift mutations
The exonic single base deletion mutations in patients FA82, FA121 
and FA199 all resulted in frameshift mutations. These mutations 
lead to premature stop codons and to the production of truncated 
and non-functional proteins. In FA82, the new open reading frame 
erroneously incorporated an additional 17 amino acids, FA121 had 
an additional 6 amino acids and FA199 had an additional 11 amino 
acids before the new premature stop codon.
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Splice mutations
A novel c.1636+1G>A mutation was discovered in intron 12 in the 
FANCG gene of patient FA465. This position is part of the splice donor 
site, and mutations here are predicted to lead to readthrough during 
mRNA processing. At the protein level, the readthrough becomes 
translated into 5 extra amino acids followed by a premature stop codon. 
Non-pathogenic mutations
Non-pathogenic mutations were identified in patients FA189 and 
FA465 (Table 1). 
In subject FA189, a novel non-synonymous c.208G>A variant was 
identified in exon 2. This novel variant was screened for in a group of 
58 random black individuals from the SA population by restriction 
enzyme analysis. It was found that the G allele occurs at a frequency 
of 0.85 (standard deviation (SD) ±0.03), while the A allele was found 
at a frequency of 0.15 (SD ±0.03) in the normal population.
The variants identified in subject FA465 (i.e. c.510+55C>T and 
c.890C>T) were classified as non-pathogenic. Neither variant was
previously reported in dbSNP,[21] Ensembl[22] or the FA mutation 
database.[23] The position of the c.510+55C>T variant within an intron 
made it unlikely to be pathogenic. HapMap data indicated that the 
allele frequency of the T allele in the c.890C>T variant is 0.125 in a 
sub-Saharan African population while that of the C allele is 0.875. 
The variant is therefore considered polymorphic in this population. 
Discussion 
A second disease-causing mutation was identified in 4/7 FA patients, 
heterozygous for the common c.637-647delTACCGCC mutation in 
the FANCG gene. Three novel single base pair deletions resulting 
in frameshift mutations (c.247delA, c.179delT and c.899delT) were 
identified and a novel single base substitution, resulting in a splice 
donor site mutation (c.1636+1G>A), was also found in this study. 
Patient FA189 was shown to have a novel, coding, non-synonymous, 
single-nucleotide polymorphism (SNP) (c.208G>A). As the A allele 
is present in 15% of the normal black population, this variant is 
predicted to be non-pathogenic. However, non-pathogenic variants 
identified in two of the patients (FA189 and FA465) could be used 
as linked markers for family studies to determine carrier status and 
for prenatal diagnosis. This is particularly true in the case of FA189, 
where a second mutation was not identified. No variants useful for 
linked marker analysis were identified in patients FA312 or FA402. 
In the three patients in whom the second pathogenic mutation 
was not identified, large deletions, insertions or rearrangements in 
the FANCG gene cannot be excluded as the cause of FA. Also, cryptic 
splice sites or mutations in control elements lying deep within an 
intron would have been missed using the approach of this study. 
True heterozygosity for the founder mutation was confirmed in 2/3 
patients by testing the parents. Somatic gene conversion of the rare 
mutation to normal cannot be excluded as DNA from peripheral 
blood was tested and the DNA from the parent with the non-founder 
mutation was not sequenced. 
Considering that only private mutations were identified in this 
study, it is possible to conclude that a second common pathogenic 
mutation in this population is unlikely to be found in the FANCG gene. 
SNP analysis may be useful in tracking the high-risk chromosome in 
families of patients where the second disease-causing mutation has 
not been identified, assuming the diagnosis is correct. 
Conclusion
Molecular diagnosis of FA in the SA context is unique in terms 
of approach: there are three large population groups in SA and 
each has a high incidence of FA. These are the black, Ashkenazi 
Jewish and Afrikaner populations. Founder mutations have been 
identified in different FA genes for each of these populations.[11,14,24] 
As such, molecular genetic diagnosis for FA in SA is specifically 
targeted depending on ethnicity (self-reported). In view of the 
limited availability of diagnostic chromosomal breakage studies, an 
alternative molecular diagnostic approach is favoured in patients 
clinically suspected to have FA. For rare individuals with a suspected 
diagnosis of FA not falling into one of these population groups, a 
testing approach taking into account the marked genetic heterogeneity 
would need to be taken.
The first-line test for individuals from the black population should 
be for the common founder mutation. Full sequencing of the FANCG 
gene is then warranted in black FA patients who are found to be 
heterozygous for the FANCG founder mutation as a second mutation 
can sometimes be identified. It is additionally recommended that the 
parents of such individuals be tested as well to exclude the possibility 
of gene conversion. The use of deletion/duplication analysis for 
FANCG still requires evaluation.
In patients in whom the FANCG founder mutation is not identified, 
FA is probably due to a gene other than FANCG. Future research could 
help to determine which other mutations in FA genes contribute to 
the remaining unidentified proportion of FA in the black population. 
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Table 1. Mutation analysis of the FANCG gene and cytogenetic tests on black FA patients heterozygous for 
c.637-643delTACCGCC (N=7)
Patient Position Genotype Effect Cytogenetic result
FA82 Exon 3 c.247delA (p.Ser83Alafs*17) Frameshift mutation (pathogenic) Positive
FA121 Exon 7 c.899delT (p.Leu300Argfs*6) Frameshift mutation (pathogenic) Positive
FA189 Exon 2 c.208G>A (p.Glu70Lys) Polymorphism (non-pathogenic) Positive
FA199 Exon 3 c.179delT (p.Leu60Profs*11) Frameshift mutation (pathogenic) Not done
FA312 - - No variation observed Not done
FA402 - - No variation observed Unsuccessful
FA465 Intron 12 c.1636+1G>A Splice donor site mutation (pathogenic)
Intron 4 c.510+55C>T Polymorphism (non-pathogenic) Not done
Exon 7 c.890C>T (p.Thr297Ile) Polymorphism (non-pathogenic)
FA = Fanconi anaemia.
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